Knowing the results of psychedelics on human brain networks is crucial to unlocking their therapeutic mechanisms. In humans, throughout the roughly six hour duration of motion, psilocybin boosts glutamate signalling and glucose metabolism19,20,21, broadly decreases the power of electrophysiological signals22, reduces hemodynamic fluctuations23 an